Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab and Domvanalimab in PD-1 Relapsed/Refractory Melanoma
NCT05130177Phase 2Active, not recruiting
- Start
- Mar 2022
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zimberelimab, domvanalimab in melanoma. Started Mar 2022; status: active, not recruiting.
02
Drugs
zimberelimabdomvanalimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05130177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130177.